Cyient
Cyient to Release Mobius, a SaaS-Based Solution for Utility Company Outage Planning and Scheduling, Powered by Microsoft Azure
Cyient, a global engineering and technology solutions company, has announced the launch of Mobius, a software-as-a-service (SaaS)-based solution and decision support platform. Mobius—hosted on Microsoft Azure—consolidates the outage planning and approval process within a central location to provide improved information flow for optimizing schedule plans.
Mobius provides customers with:
A robust and secure outage planning, scheduling, and visualization system built on a
strong communication platform for addressing ongoing and future outages and
curtailments
Transparency in communicating planned outages to all connections that may be
impacted
Reduced outages on their network and easy risk/opportunity tracking, helping reduce
outage costs that can affect operational budgets
Commenting on the launch, Kimberley Reed, Product Owner at Cyient, said, “We’re excited about the launch of Mobius. Planned network outages are a routine requirement for most utilities. With the growing need for decarbonization initiatives and increasing number of distributed energy resource (DER) customers connecting to existing networks, utilities are faced with the challenge of improved communication and transparency of planned outages with DER customers.”
In developing Mobius, Cyient extensively employed the following Microsoft offerings:
a. Azure DevOps was used to manage the solution backlog and roadmap, enabling
continuous enhancement and functionality for Mobius with minimal disruption
during customer rollouts.
b. Azure provides a scalable environment to offer Mobius as a SaaS solution by boosting
connectivity among corporate users and accounts, as well as between external DER
customers and network planners.
c. Azure Portal is employed to manage application elements.
d. Azure Blob Storage is used to store outages and site attachments so they can be
created and viewed by all users in a centralized location.
e. Azure Application Insights and Dashboards enables the Cyient product support team
via the continuous monitoring of the application and microservices.
f. Azure SQL Database provides the ability to manage and easily scale the database as
required.
“The Microsoft Azure cloud platform was the development back end for Mobius. Integration with Azure DevOps completely removed any manual deployment tasks and provided a repeatable deployment process that enabled Cyient to focus on testing, with the certainty that any issues after deployment would be the result of code changes rather than missed dependencies during deployment,”Reed explained. “Azure DevOps provided a centralized tool to enable us to manage our product backlog, define sprints, and store our code in the Git-backed code repository. This greatly simplified the product release process and subsequent rollout to customers and end-users.”
Glenmark Pharmaceuticals Ltd
Glenmark launches Tiogiva®, becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler
Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, becomes one of the first companies to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name - Tiogiva®, in UK for the treatment of chronic obstructive pulmonary disease (COPD).
COPD is a long-term condition that causes inflammation in the lungs, damaged lung tissue and a narrowing of the airways, making breathing difficult. There are many different types of the condition, although little is known about what causes this variation and the best way to manage the different versions of the disease1 .
According to data from IQVIA, Tiotropium DPI had a market size of US$ 450 Mn in the EU in the 12 month period ended September 2020
Glenmark’s subsidiary, Glenmark Pharmaceuticals Europe Limited had entered into a strategic, exclusive inlicensing arrangement for marketing generic Tiotropium Bromide DPI in Western Europe and UK in August 2018. Glenmark is planning subsequent launches of the product across markets in Western Europe under the brand name Tiogiva® in Ireland, Sweden, Finland and Norway; Tavulus® in Denmark, Spain and Netherlands; and Tiotropium Glenmark® in Germany.
Tiotropium Bromide DPI is a bioequivalent version of Boehringer Ingelheim’s Spiriva® Handihaler® and is used in the treatment of COPD
This is the second inhalation product in-licensed by Glenmark for the European market after Stalpex® (Fluticasone/ Salmeterol) dry powder inhaler.
“We are glad to introduce Tiogiva®, one of the first bioequivalent drugs to be launched in Europe for treatment of COPD. Respiratory medicine is a key area of focus for Glenmark and the launch of this product will enable us to improve access to COPD treatment by providing an effective and high quality treatment option to patients in UK and Western Europe,” said Achin Gupta, EVP & Business Head of EMEA-L, Glenmark Pharmaceuticals Ltd.
Quick Heal Technologies Limited
Seqrite launches ‘Seqrite Hawkk’ to help enterprises secure their digital transformation journey
Seqrite, a specialist provider of enterprise cybersecurity products and solutions has introduced ‘Seqrite Hawkk’, a premium suite of next-generation cybersecurity solutions aimed at empowering enterprises to secure their digital transformation journey. In the first phase, Seqrite Hawkk will offer – ‘Seqrite HawkkEye’ – a cloud based centralized security management platform that will empower enterprises to manage multiple security products from a single console. Seqrite will continue to invest and add more products under the Hawkk umbrella that will also mark the brand’s foray into endpoint detection and response (EDR), zero trust, data privacy and cloud-based network security products
Seqrite is the enterprise arm of Quick Heal Technologies Limited, one of the leading providers of cybersecurity products and solutions for consumers, businesses and Government. In 2020 alone, Seqrite successfully thwarted over 13,000 cyber-attacks every hour, including ransomware (double extortion), APTs and targeted attacks, demonstrating the scale and sophistication of cyber-attacks
According to the data from the Indian Computer Emergency Response Team (CERT-In), India witnessed a 300% rise in cyber-attacks in 2020. Rapid proliferation of endpoints, cloud apps, and smartphones with the growth of distributed workspaces and a diminishing enterprise perimeter has exposed organizations to newer threat vectors and risks. Security point products in play fail to consider the aggregated impact of a security alert and often employ a siloed approach to threat remediation. The growing threat landscape needs a centralized and integrated security and risk management approach
‘Seqrite Hawkk’ has been designed to empower CISOs and IT leaders to get comprehensive visibility into their organization’s security posture, generate actionable insights, ensure compliance and boost their organization’s defense against the next wave of cyber-attacks across endpoints and mobile devices, enterprise data infrastructure, and enterprise applications. Powered by AI, Cloud and Patented technologies, the new range of solutions are easy to use, lightweight and can be deployed within minutes. The launch demonstrates Seqrite’s continuous commitment towards innovating and developing the most comprehensive and powerful suite of security solutions to simplify cybersecurity management.
.